ASX:NVO Novo Resources (NVO) Stock Price, News & Analysis → The Best AI Stock to Own in the World Today is Trading for Just $25 (From Banyan Hill Publishing) (Ad) Free NVO Stock Alerts Add Compare Share Share Today's Range N/A50-Day Range N/A52-Week Range N/AVolumeN/AAverage VolumeN/AMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Novo Resources alerts: Email Address Ad InvestorPlaceYou need to know these two things about AI stocks ASAP…For 40 years, he's been known as one of the world's most bullish investors. Forbes even referred to him a "perma bull"... But he just shocked the world by issuing a massive bear warning about AI stocks.Go here now for this breaking story. About Novo Resources Stock (ASX:NVO)Novo Resources Corp., together with its subsidiaries, engages in evaluating, acquiring, exploring, and developing natural resource properties in Canada, Australia, and the United States. The company primarily explores for gold deposits. It holds approximately 7,500 sq km of land in the Pilbara region of Western Australia, as well as interests in various projects located in Victoria, Australia. The company was formerly known as Galliard Resources Corp. and changed its name to Novo Resources Corp. in June 2011. Novo Resources Corp. was incorporated in 2009 and is headquartered in Vancouver, Canada.Read More Ad InvestorPlaceYou need to know these two things about AI stocks ASAP…For 40 years, he's been known as one of the world's most bullish investors. Forbes even referred to him a "perma bull"... But he just shocked the world by issuing a massive bear warning about AI stocks.Go here now for this breaking story. NVO Stock News HeadlinesMay 6, 2024 | ca.finance.yahoo.comCanadian Investment Regulatory Organization Trading Halt - NVO.WT.AMay 6, 2024 | msn.comGates, Novo Nordisk And Wellcome Commit $300 Million To Climate Change, Infectious Diseases And NutritionMay 10, 2024 | Crypto Swap Profits (Ad)Claim Your Complimentary Bitcoin RewardMany have already secured their free Bitcoin reward offered by our esteemed guest. How about you? In an effort to spread the word about our upcoming workshop, he's generously offering $10 in Bitcoin (BTC) to participants. Absolutely no strings attached.May 4, 2024 | theglobeandmail.comNovo Resources: Top 10 Undervalued Growth Stocks on TSX (NVO)May 2, 2024 | morningstar.comNovo Nordisk Earnings: Raised Fair Value Estimate Still a Contrast to Market OverenthusiasmMay 2, 2024 | msn.comNovo Nordisk Investing $6 Billion to Increase Access to Ozempic and Wegovy amid Nationwide ShortageMay 2, 2024 | seekingalpha.comWall Street Breakfast: As It MayMay 2, 2024 | msn.comNovo Nordisk trims price for blockbuster obesity drug as competition heats upMay 10, 2024 | Crypto Swap Profits (Ad)Claim Your Complimentary Bitcoin RewardMany have already secured their free Bitcoin reward offered by our esteemed guest. How about you? In an effort to spread the word about our upcoming workshop, he's generously offering $10 in Bitcoin (BTC) to participants. Absolutely no strings attached.May 2, 2024 | msn.comOzempic Maker Novo Nordisk Beats Profit Forecasts Amid Weight Loss Drug FrenzyMay 2, 2024 | msn.comNovo Nordisk Lifts Guidance as Blockbuster Drug Demand Shows No Signs of AbatingMay 2, 2024 | marketwatch.comNovo Nordisk Raises FY Sales and Op Profit GuidanceMay 2, 2024 | money.usnews.comObesity Drugmaker Novo Nordisk Raises Outlook, Q1 Profit Beats ForecastMay 1, 2024 | nytimes.comGetir, a Rapid Grocery-Delivery Service, Exits the U.S. and EuropeApril 29, 2024 | msn.comAncient ‘Paleo’ diet largely consisted of plants for some hunter-gatherers, study findsApril 29, 2024 | marketwatch.comNovo Nordisk Earnings Expected to Rise Further, With Production in Focus -- Earnings PreviewApril 26, 2024 | marketwatch.comNovo Nordisk Probed by Senate Committee on Weight-Loss Drug PricesApril 24, 2024 | seekingalpha.comNovo Nordisk comes under Senate probe over pricing for weight loss drugsApril 23, 2024 | msn.comCompare with FTSE Novo-Nordisk B Index (SSNOVO)April 20, 2024 | nytimes.comInside Novo Nordisk’s HeadquartersApril 17, 2024 | msn.comOzempic isn't linked to suicidal thoughts, U.S. and European health agencies findApril 17, 2024 | msn.comHealthy Returns: U.S. drug shortages reach record high, hitting Wegovy, ADHD medicationsApril 17, 2024 | theglobeandmail.comInternships, youth programs key to developing the next generation of talentApril 12, 2024 | msn.comNovo Nordisk's Dominance In Obesity & Diabetes Drug Market Backed by Strong Pipeline: Analyst Gives Outperform RatingApril 12, 2024 | msn.comEU Probe Finds No Added Suicide Risk Linked to Novo’s WegovyApril 8, 2024 | msn.comI Invested in Ozempic—It Taught Me a Valuable LessonApril 7, 2024 | msn.comWeight-loss drug Wegovy offers benefits for people with diabetes and common form of heart failure, study findsSee More Headlines Receive NVO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Novo Resources and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeASX SectorBasic Materials Industry Gold Sub-IndustryN/A Current SymbolASX:NVO CUSIPN/A CIKN/A Webwww.nvoi.com.au Phone1300 687 179FaxN/AEmployees75Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)A($0.18) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-48,890,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-35.83% Return on Assets-13.65% Debt Debt-to-Equity Ratio1.90 Current Ratio2.66 Quick Ratio4.30 Sales & Book Value Annual Sales$2.50 million Price / Sales0.00 Cash FlowN/A Price / Cash Flow2.25 Book ValueA$0.24 per share Price / BookN/AMiscellaneous Outstanding Shares354,630,000Free FloatN/AMarket CapN/A OptionableNot Optionable Beta1.59 Investing Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free Report Key ExecutivesMr. Michael John Spreadborough MBAExecutive Co-Chairman & Acting CEOMs. Karen De LucaGeneral Manager of ExplorationMs. Elza van der WaltCFO & Joint Corporate SecretaryMs. Lisa SmithGeneral Counsel & Joint Corporate SecretaryMr. Alwin van RoijSenior Exploration GeologistKey CompetitorsAben MineralsOTCMKTS:ABNAFAdelong GoldASX:ADGAlacer GoldOTCMKTS:ALIAFALACERGOLD/IDR UNRESTRASX:AQGAlchemy ResourcesASX:ALYView All Competitors This page (ASX:NVO) was last updated on 5/10/2024 by MarketBeat.com Staff From Our PartnersThe Crypto 9-5 Escape PlanCrypto 101 MediaGold Set to EXPLODE!Gold Safe ExchangeHe Is Giving Away BitcoinCrypto Swap ProfitsForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill PublishingCharles Payne Demystifies OptionsUnstoppable ProsperityShocking: One AI startup's revenue could surge 4,735%Manward PressThe 2024 Gold Rush: Unleashing Market PotentialPriority Gold[URGENT] DO NOT Touch These AI Stocks!Weiss Ratings Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Novo Resources Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.